Skip to main content
. 2021 Nov 26;77(10):976–986. doi: 10.1136/thoraxjnl-2021-217463

Figure 5.

Figure 5

Base case cost-effectiveness acceptability curve. The graph plots the probability that domiciliary NIV is cost-effective at various UK thresholds for willingness to pay for 1 QALY (£/QALY). Above thresholds of £40 000 per QALY, it can be seen NIV emerges as likely to be cost-effective. ICER, incremental cost-effectiveness ratio; NIV, non-invasive ventilation; P, probability; QALY, quality-adjusted life years.